Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Krankenhaus Nordwest
- Target Recruit Count
- 143
- Registration Number
- NCT00737373
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 159
- Registration Number
- NCT00707889
- Locations
- 🇺🇸
Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States
🇺🇸Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States
🇦🇺Site Reference ID/Investigator# 18581, Bedford Park, Australia
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00673179
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00663481
- Locations
- 🇺🇸
Parexel International - Baltimore CPRU, Baltimore, Maryland, United States
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 214
- Registration Number
- NCT00642577
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00642746
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- BTG International Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00634322
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
- Conditions
- Interventions
- Drug: GemcitabineDrug: NavelbineDrug: Doxorubicin Hydrochloride Liposome InjectionDrug: Granulocyte-colony stimulating factor (G-CSF)Drug: PegfilgrastimDrug: CyclophosphamideDrug: VincristineDrug: LeucovorinDrug: MethotrexateDrug: Doxorubicin HydrochlorideDrug: CytarabineDrug: EtoposideDrug: CarmustineDrug: Denileukin diftitox
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT00632827
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00577109
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00559455
- Locations
- 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.